Search results

Compounds(Page)
Several NCE's in Our R&D Program In order to create these compounds, novel chemical spacers were invented by Dr. Adrian Harel. These spacers a...

Science Park Medicortex Finland(Page)
ce of the Month Turku Science Park Israeli neurobiologist Adrian Harel founded in Turku a company called Medicortex Finland which develops dru...

Board and Management(Page)
ist has decades of experience in general practice and scientific work in medicine, having held positions as Adjunct Professor in two major uni...

Dr. Harel is the Face of the Month in Turku Science Park's Newsletter(News)
of the Month in Turku Science Park's Newsletter Israeli neurobiologist Adrian Harel founded in Turku a company called Medicortex Finland w...

Dr. Harel attended the 7th International Conference on Biochemical Markers for Brain Damage(News)
ext">BMDB 2015 conference in Lund, Sweden from September 14th to the 16th. The conference included commercial and academic interaction...

Dr. Adrian Harel Presented TBI at Life Sciences Israel 2015(News)
href="http://www.lifesciencesisrael.com/" class="">here...

Dr. Kvist attending Clinical Trials Excellence Forum 2016(News)
in Clinical Trials Excellence Forum 2016 (12. - 14. October, Munich)...

Dr. Harel will attend the European Life Sciences CEO Forum(News)
Annual European Life Sciences CEO Forum & Exhibition.The event will take place on 6th to 7th March 2017 in Zurich, Switzerland...

Medicortex Finland Is Developing Diagnostic Tool Based on Biomarkers for Traumatic Brain Injury and Stroke(News)
ot only diagnose the presence of a brain injury, it will also quantify its severity and indicate the treatment needed. In addition, the kit co...

Drs. Harel & Kvist attended the BAF Live! event in Helsinki on 22nd of October(News)
Live! people at the residence of the Dutch Ambassador, Cees Bansema, on 22nd of October. Photo taken and copyrighted by Replay Factory. Drs...

Tom Palenius joins Medicortex's Board of Directors(News)
ng activities of Life Science business...

Company Profile(Page)
located in the Turku Science Park Bioincubator. Tekes -  the Finnish Funding Agency for Innovation has awarded Medicortex a grant and a long ...

Technology(Page)
y will verify its novel concept in several animal models of neurodegenerative conditions, including head trauma and stroke, in the hope of obt...

Diagnostics(Page)
called Chronic Traumatic Encephalopathy (CTE). Victims of CTE, who have lately been in the news due to their involvement in high profile athle...

R&D Programs(Page)
t of the diagnostic kit. Once the Biomarker program is advanced we will focus on the Drug development program. All the requirements of clinica...

Business Strategy(Page)
help establish the existence of a mild brain trauma. Medicortex's novel, multi-functional approach at treating TBI and stroke aims at decreas...

Our Vision(Page)
equire increased surveillance, or for those individuals with mild TBI, who otherwise may remain undiagnosed and untreated. A diagnostic test c...

Kansanterveys(Page)
patia (Chronic Traumatic Encephalopathy, CTE) ovat huomattavia kansanterveydellisiä ongelmia, joita on kutsuttu myös “hiljaiseksi epidemiaksi”...

Clinical trials(Page)
ntly running a proof-of-concept clinical trial in collaboration with Turku University Hospital (Tyks). Samples from 12 head-injured patients a...

Why to invest?(Page)
eclinical and proof-of-concept human testing). - Patent applications and PCT filed. - Exciting Company, won twice an innovation prize. Why to...

Miksi sijoittaa?(Page)
en tutkimus ja proof-of-concept tutkimus ihmisillä). - Patenttihekemuksia ja PCT-hakemus jätetty - Kiinnostava yhtiö, voittanut kahdesti innov...

Art Helping TBI Research(News)
an alternative way to finance our research & development program for a Brain injury diagnostic kit based on biomarkers and in the future d...

Medicortex's Annual General Meeting on May 30th(News)
ke place in the Turku Science Park Bioincubator on the 30th of May. All shareholders are invited to take part in the meeting...

The First Clinical Trial is Approaching(News)
the Q4 of 2016. The presence and the profiles of the unique biomarkers will be studied and compared between head injured patients and healthy...

Extraordinary general meeting 29th September(News)
t 5.00 p.m. in the conference room of the Bioincubator (PharmaCity, Itäinen pitkäkatu 4 B, 4th floor, Turku, Finland).It's possible to...

Medicortex has completed collection of clinical samples(News)
We are happy to announce that we have completed the collection of clinical TBI patient samples in collaboration with Turku University Hosp...

Medicortex has launched a crowdfunding campaign(News)
wdfunding campaign to finance the next phase development of the brain injury test. You can help us to develop a rapid diagnostic kit for brain...

Clinical Trial Result Marks a Significant Accomplishment for Medicortex Finland(News)
a significant proof-of-concept and it represents a remarkable milestone for Medicortex. Please see the ...

Medicortex's Annual General Meeting on May 29th(News)
ke place in The Turku Science Park Bioincubator on the 29th of May 2017 at 15:00. All current shareholders are invited to take part and attend...

A New Clinical Trial for a Novel Brain Injury Biomarker(News)
land Oy was granted clearance to begin a multi-center clinical trial. The trial will consist of patients that are admitted to emergency rooms...

The 24th Annual Israel Society for Neuroscience Meeting(News)
Dr. Adrian Harel will be attending and presenting a poster session at the 24th annual ISFN meeting in Eilat on the 20th to 22nd o...

Medicortex participated in a press conference #pääasia(News)
Medicortex's medical director Mårten Kvist participated on a panel discussion of #pääasia- media event 7.11. in Biocity Turku. Fo...